Business Context and Reporting Period
This Form 8-K Current Report was filed by India Globalization Capital, Inc. (not IGC Pharma, Inc.) on October 1, 2018. The filing discloses the entry into a material definitive agreement to establish an At-the-Market (ATM) equity offering program.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial figure disclosed relates to the potential capital raise:
- Maximum Offering Size: Up to $15,000,000 of common stock.
- Agent Commission: 5.0% of gross proceeds from sales.
Material Changes
The material change reported is the execution of an ATM Agency Agreement with The Benchmark Company, LLC and ViewTrade Securities, Inc. This agreement authorizes the managers to sell shares of the company's common stock on the NYSE American or other trading markets. The agreement is set to automatically terminate on May 10, 2021, unless terminated earlier.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance or management commentary on future performance. Key terms and contingencies include:
- Sales Method: Shares will be sold directly on trading markets or through market makers; privately negotiated transactions require prior written approval.
- Suspension Rights: The Company or the Managers may suspend the offering upon notice.
- Legal Basis: Shares are issued pursuant to a shelf registration statement on Form S-3 (File No. 333-224082) declared effective on May 11, 2018.
- Indemnification: The Company has agreed to indemnify the Managers against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the company name is India Globalization Capital, Inc., as the input metadata referenced "IGC Pharma, Inc."
- Confirm the status of the Form S-3 shelf registration (File No. 333-224082) to ensure it remains effective for future sales.
- Review the full text of the At-The-Market Offering Agreement (Exhibit 10.1) for specific covenants and termination clauses.
- Monitor future filings for actual sales volumes and proceeds generated under this ATM program.